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Abstract
Introduction: In this study we aimed to investigate whether there are indications of premature atherosclerosis, as
measured by endothelial dependent flow-mediated dilation (ED-FMD) and intima media thickness (IMT), in patients
with very early RA, and to analyze its relation to biomarkers of endothelial dysfunction, taking inflammation and
traditional cardiovascular disease (CVD) risk factors into account.
Methods: Patients from the three northern counties of Sweden diagnosed with early RA are followed in an
ongoing prospective study of CVD co-morbidity. Of these, all patients aged ≤60 years were consecutively included
in this survey of CVD risk factors (n = 79). Forty-four age and sex matched controls were included. IMT of common
carotid artery and ED-FMD of brachial artery were measured using ultrasonography. Blood was drawn for analysis
of lipids, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), plasminogen activator inhibitor-1 (PAI-1),
tissue plasminogen activator (tPA)-mass, VonWillebrand factor (VWF), soluble intercellular adhesion molecule-1
(sICAM), soluble vascular cell adhesion molecule-1 (sVCAM), sE-selectin, sL-selectin and monocyte chemotactic
protein-1 (MCP-1). In a subgroup of 27 RA patients and their controls the ultrasound measurements were
reanalysed after 18 months.
Results: There were no significant differences between RA patients and controls in terms of IMT or ED-FMD at the
first evaluation. However after 18 months there was a significant increase in the IMT among the patients with RA
(P < 0.05). Patients with RA had higher levels of VWF, sICAM-1 (P < 0.05) and of MCP-1 (P = 0.001) compared with
controls. In RA, IMT was related to some of the traditional CVD risk factors, tPA-mass, VWF (P < 0.01) and MCP-1
and inversely to sL-selectin (P < 0.05). In RA, ED-FMD related to sL-selectin (P < 0.01). DAS28 at baseline was related
to PAI-1, tPA-mass and inversely to sVCAM-1 (P < 0.05) and sL-selectin (P = 0.001).
Conclusions: We found no signs of atherosclerosis in patients with newly diagnosed RA compared with controls.
However, in patients with early RA, IMT and ED-FMD were, to a greater extent than in controls, related to
biomarkers known to be associated with endothelial dysfunction and atherosclerosis. After 18 months, IMT had
increased significantly in RA patients but not in controls.
Introduction
Patients with rheumatoid arthritis (RA) have an
increased morbidity and mortality due to cardiovascular
disease (CVD) [1,2]. Traditional cardiovascular (CV)
risk factors cannot fully explain the increase but
inflammation has been shown to contribute to the
increased CVD among these patients [3-6]. We, and
others, have previously shown that patients with RA
have premature atherosclerosis as measured by
increased intima media thickness (IMT) of the common
carotid artery compared with controls [6-9]. Increased
IMT, measured by ultrasound, is regarded as an early
indicator of overall atherosclerosis [10], and several stu-
dies on IMT in the general population have shown a
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[11,12]. Among patients with RA, increased IMT has
been associated with traditional CV risk factors, includ-
ing age and sex, markers of inflammation and disease
duration [6,7,9]. Almost all of these studies are, how-
ever, cross-sectional and comprise patients with long-
standing RA.
Endothelial dysfunction, a sign of very early athero-
sclerosis, can be assessed by impaired endothelial depen-
dent flow-mediated vascular dilation (ED-FMD) of
peripheral arteries, measured by ultrasonography [13].
In the general population, ED-FMD was associated with
other risk factors for CVD, predictive of a future CV
event, and reversible by treatment with cardioprotective
drugs [14]. Studies on patients with RA have been small,
and nearly all comprised only patient cohorts with long-
standing disease [15,16]. There are also several studies
on ED-FMD that analyze treatment outcomes in RA
[17,18], but only one so far evaluating patients with
early RA [19].
In addition to physiological manifestations, the athero-
sclerotic process appears to be associated with altera-
tions in biomarkers of inflammation, haemostasis and
endothelial function. Several studies have investigated
different biomarkers, for example, soluble vascular cell
adhesion molecule-1 (sVCAM-1), soluble intercellular
adhesion molecule-1 (sICAM-1), soluble (s)E-selectin
[20,21], monocyte chemotactic protein-1 (MCP-1)
[22,23], soluble (s)L-selectin [24], plasminogen activator
inhibitor-1 (PAI-1), tissue plasminogen activator (tPA)
and VonWillebrand factor (VWF) [21,25] for an associa-
tion with endothelial dysfunction, atherosclerosis and/or
CVD in the general population. We and others have
previously shown associations in patients with RA
between atherosclerosis and sICAM-1, sE-selectin and
PAI-1 [7,26,27] and between endothelial dysfunction
and sVCAM-1 and sL-selectin [28]. Other studies on
patients with RA have shown an association between
IMT and VWF [8] as well as sVCAM-1 [27]. Further-
more, studies have shown higher levels of mass concen-
trations of tPA and PAI-1 in addition to higher levels of
VWF, sVCAM-1, sICAM-1 and sE-selectin in RA
patients compared with healthy controls [7,27,29]. How-
ever, there are no studies in this respect in patients with
early RA. Our hypothesis evaluated in this study was
that premature atherosclerosis, and biomarkers of
endothelial dysfunction, would be already present in
patients with newly diagnosed RA.
From an ongoing prospective case-control study we
here present the first cross-sectional baseline data as
well as data on progression of atherosclerosis after 18
months. Our primary aim was to investigate whether
signs of atherosclerosis, as measured by IMT and ED-
FMD, were present in patients with very early RA
compared with controls at baseline and after a period of
18 months. The second aim was to identify biomarkers
of endothelial activation of particular interest in RA, col-
lected at baseline, that could reflect early atherosclerosis
in the context of inflammation.
Materials and methods
Patients and controls
This study is part of a continuing structured programme
on early RA, using the nationwide Swedish Rheumatoid
Arthritis Registry. All eligible patients with newly diag-
nosed RA [30] and being symptomatic for no longer
than 12 months are continuously enrolled into the regis-
ter. Between 2000 and 2004 all patients under 60 years
of age from the three most northern counties of Sweden
were consecutively invited to participate in an extended
survey on CV morbidity; 79 patients agreed to partici-
pate, and were enrolled into this study whilst six
patients declined participation, one was pregnant and
another was excluded due to advanced breast cancer.
Forty-four controls without RA were assembled, of
whom 39 were randomly selected from the population
register of the same region. In order to include appro-
priate very young (21-27 years old) controls, three hos-
pital staff and two students were recruited at random.
The controls (one control for two patients, but in nine
cases one control per patient) were matched for age
(± 5 years) and sex. All individuals gave their written
consent in accordance with the Declaration of Helsinki.
The study was approved by the Regional ethics commit-
tee of Umeå University, Umeå, Sweden.
Physical examination and surveys
All patients were examined clinically at inclusion into
the study. The number of swollen and tender joints (28
j o i n tc o u n t )a n dp a t i e n t ’s global assessment were regis-
tered and a disease activity score (DAS28) including ery-
throcyte sedimentation rate (ESR) calculated [31]. All
participants were requested to complete a health assess-
ment questionnaire (HAQ) [32], a survey on co-morbid-
ity, including any previous CVD event as defined by
acute myocardial infarction, stroke or coronary artery
bypass surgery, and a survey of CVD risk factors and
life style [33]. Body mass index (BMI) was calculated.
Medical treatments at the time of the first ultrasound
measurements are presented in Table 1.
Ultrasound investigations
Ultrasound examinations were performed as soon as
possible after the first symptoms of RA, and no longer
than 12 months after diagnosis (mean 16.2 ± 6.6
months after the first symptom). All examinations
were performed by the same experienced investigator
with the individuals in a supine position in a quiet,
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sound system (Siemens (Acuson) Corp, Upplands-
Väsby, Sweden) was used with a 15L8 transducer for
brachial artery and a 8L5 transducer for carotid artery
studies. All investigations were digitally stored for ana-
lyses, which were performed by a single observer (EL,
intraobserver variability r = 0.988) on a Sequoia 512.
R-wave triggered end diastolic right brachial artery
longitudinal images proximal to the ante cubital fossa
were recorded at baseline after 15 minutes of supine
rest. Transducer position was carefully noted for subse-
quent investigations. For ED-FMD R-wave triggered
images were stored for 90 seconds following ischaemia.
The ischaemia was induced using a cuff on the forearm
inflated 20 mmHg above the systolic blood pressure for
five minutes with additional lower arm muscular work
by repetitively squeezing a s m a l lb a l ld u r i n gt h el a s t
minute of ischaemia. Maximal brachial artery diameter
was calculated for both conditions as a mean of three
measurements. ED-FMD was calculated as a percentage
of the baseline diameter.
Carotid artery studies were performed with the indivi-
dual in the supine position with the neck extended and
the chin turned away from the side being examined.
The right common carotid artery proximal to the bulb
was imaged in multiple longitudinal planes for the best
resolution of the IMT of the far wall. The IMT was
obtained manually tracing the intima-media in the far
w a l lo ft h ea r t e r yf o rad i s t a n c eo fa p p r o x i m a t e l y
10 mm. Measurements were performed on three end
diastolic images and averaged.
I nas u b g r o u po f2 7p a t i e n t sw i t hR Aa n dt h e i rc o n -
trols, the ultrasound measurements were retaken
18 months (± 2 weeks) after the first ultrasound
investigation.
Blood sampling
In the present study all patients and controls donated a
blood sample at the time of the first ultrasound measure-
ment. This was separated into plasma, serum and buffy
coat and stored at -80°C. After thawing, sVCAM-1 (ng/
mL), sICAM-1 (ng/mL), sL-Selectin (ng/mL) and sE-
Selectin (ng/mL) were measured on serum using ELISA
(R&D Systems, Abingdon, UK) and MCP-1 (pg/mL)
using ELISA (HyCult Biotechnology, Uden, The Nether-
lands). Mass concentrations of PAI-1 (μg/L) and tPA
(μg/L) were measured on plasma using ELISA (Trinity
Biotech Inc, Bray, Ireland) and VWF (%) using ELISA as
previously described [34]. The presence of antibodies
against cyclic citrullinated peptide (anti-CCP) in serum
was detected using the Diastat kit (Axis-Shield Diagnos-
tics, Dundee, UK) with a cut-off value of 5 units/mL.
Blood was also drawn after an overnight fast for analysis
of blood lipids: cholesterol (mmol/L), high-density lipo-
proteins (HDL; mmol/L) and triglycerides (mmol/L) were
measured by routine methods at each of the hospitals.
When a diagnosis of RA was confirmed, rheumatoid fac-
tor (RF) and soluble C-reactive protein (CRP; mg/L) were
measured according to routine methods at each of the
hospitals and ESR (mm/h) was measured according to
the Westergren method. ESR and CRP were also mea-
sured every three months thereafter. CRP of 10 mg/L or
less was set at the cut-off level, 10 mg/L, in the statistical
calculations. Whenever several analyses of DAS28, CRP
or ESR were performed the assessment closest to the
ultrasound measurement was used in the statistical ana-
lyses, that is, with a time lag that was at most six weeks
but in most cases much shorter.
Statistics
Differences in variables between patients with RA and
matched controls were analyzed using simple conditional
Table 1 Demographic data and traditional CVD risk
factors in patients with early RA and age- and
sex-matched controls
RA (n = 79) Controls (n = 44)
Women 64 (80%) 34 (77%)
Age, years 46.4 (10.7) 47.7 (11.1)
Systolic blood pressure, mmHg 123.6 (14.3)* 117.4 (11.0)
Diastolic blood pressure, mmHg 77.3 (8.6) 76.3 (8.3)
Heart rate, beats per minute 72.3 (10.5) 67.9 (9.4)
Cholesterol, mmol/L 5.40 (0.96) 5.39 (1.15)
Triglycerides, mmol/L 1.25 (0.49)* 1.06 (0.38)
HDL, mmol/L 1.52 (0.53) 1.44 (0.39)
BMI, kg/m
2 25.7 (4.0) 25.1 (4.9)
Smoking, years 13.75 (14.32)* 6.96 (10.33)
Oral snuff, years 3.12 (8.01) 2.57 (7.39)
Diabetes mellitus 5 (6%) 1 (2%)
Previous CVD event 5 (6%) 1 (2%)
Postmenopausal 25 (42%) 16 (47%)
University education 23 (30%) 20 (46%)
Familial history of CVD 17 (24%) 7 (18%)
Treatment with NSAIDs 35 (50%) 2 (5%)
Treatment with coxibs 9 (13%) 1 (2%)
Treatment with statins 2 (3%) 1 (2%)
Treatment with corticosteroids 26 (38%) —
Treatment with DMARDs 74 (97%) —
Data are expressed as mean value (standard deviation) or number of
individuals (percentage for whom data are given).
* P < 0.05, ** P < 0.01, *** P < 0.001.
The DMARDS patients received were 41 methotrexate, 12 sulphasalazine,
1 oral gold, 8 were receiving a combination of methotrexate and
hydroxychloroquine phosphate, 4 a combination of methotrexate and
sulphasalazine, 2 had a combination of methotrexate, sulphasalazine and
hydroxychloroquine phosphate and 1 had a combination of methotrexate,
sulphasalazine and etanercept.
BMI, body mass index; CVD, cardiovascular disease; DMARDs, disease-
modifying antirheumatic drugs; HDL, high-density lipoproteins; NSAIDs, non-
steroidal anti-inflammatory drugs; RA, rheumatoid arthritis.
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group were performed using the Mann-Whitney U-test
or, for comparsions over time, the Wilcoxon paired test.
Simple and multiple linear regression analyses were used
to identify variables associated with ED-FMD, IMT and
the biomarkers. Simple linear regression (variables with P
< 0.05) together with clinical assumptions, determined
which co-variates were included in the multiple linear
regression models. To check the assumption of linearity,
continuous variables were also categorised according to
their tertiles and included in a regression model, but all
variables were considered as linear. Based on results from
previous publications, calculations showed that a sample
size of 26 in each group would render 95% power to
detect a difference in IMT of 0.1 ± 0.1 mm between the
groups. In some of the descriptive statistics there are
occasionally missing values due to missing information,
these missing values can be regarded as random. P < 0.05
were considered statistically significant. All calculations
were made using SPSS 15.0 (SPSS Inc, Chicago, IL, USA).
Results
Baseline data
Data on demographics and traditional CV risk factors
are given in Table 1. The patients with RA had signifi-
cantly higher systolic blood pressure, higher levels of tri-
glycerides and more years of smoking compared with
the controls at baseline.
There were no significant differences between patients
and controls regarding any of the ultrasound measure-
ments at baseline (Table 2).
Fifty-five out of 78 (71%) patients were RF seropositive
and 50 of 78 (64%) had anti-CCP antibodies. Data on
inflammation in patients with RA are given in Table 3.
Compared with controls, patients with RA had signifi-
cantly higher levels of, sICAM-1, MCP-1 and VWF,
w i t hat e n d e n c ya l s of o rs V C A M - 1t ob eh i g h e r( P =
0.059; Table 3). The statistically significant differences in
VWF, sICAM-1 and MCP-1 levels remained after
adjustment for sex, age, smoking, systolic blood pressure
or any of the lipids (data not shown).
In the RA patients, IMT at baseline was significantly
related to some of the traditional CVD risk factors when
analyzed in simple linear regression models (Table 4).
Regarding endothelial biomarkers, IMT was significantly
related to tPA-mass, VWF, sL-selectin and MCP-1 and
ED-FMD was significantly related to PAI-1 and sL-selec-
tin (Table 4).
Among the controls, IMT was significantly related to
systolic blood pressure (b =0 . 0 7 ,P < 0.001), age (b =
0.08, P < 0.001), triglyceride level (b =2 . 3 ,P <0 . 0 0 1 ) ,
cholesterol level (b =0 . 6 ,P < 0.001), HDL level (b =
-1.6, P < 0.01), BMI (b =0 . 1 ,P < 0.05) and female sex
(b = -2.1, P < 0.001), but regarding biomarkers only to
tPA-mass (b =0 . 2 ,P < 0.01) and sL-selectin (b = -1.8,
P < 0.05). In the controls ED-FMD was significantly
related only to MCP-1 (b = -33.4, P < 0.05). There were
no other statistically significant relations between ultra-
sound measurements and risk factors in patients or con-
trols at baseline (data not shown).
There was no relation between any of the disease
activity measurements, that is, DAS28, HAQ, ESR
and CRP level, and the ultrasound measurements in the
RA patients at the time of the baseline investigation.
Nor were there any relations between any of the
Table 2 Baseline measurements of intima media thickness and flow mediated dialtation in patients with early RA and
age- and sex-matched healthy controls
RA (n = 79) Controls (n = 44)
Intima media thickness, mm 0.52 (0.13) 0.55 (0.15)
Baseline diameter of a brachialis, mm 3.5 (0.07) 3.5 (0.05)
Endothelium-dependent flow mediated vasodilatation, % 108.9 (4.7) 107.2 (4.6)
Data is given as mean value (standard deviation).
RA, rheumatoid arthritis.
Table 3 Endothelial biomarkers and markers of
inflammation in patients with early RA and age- and sex-
matched healthy controls
RA (n = 79) Controls (n = 44)
sVCAM-1, ng/mL 742.7 (237.9) (*) 631.4 (173.2)
sICAM-1, ng/mL 354.1 (131.8)* 290.6 (66.9)
sE-selectin, ng/mL 51.8 (19.2) 53.8 (16.7)
sL-selectin, ng/mL 1252.0 (306.2) 1279.7 (273.2)
MCP-1, pg/mL 1945.6 (936.9)*** 1125.1 (475.5)
PAI-1, μg/L 64.1 (37.3) 59.1 (28.7)
tPA-mass, μg/L 7.17 (3.04) 8.06 (4.32)
VWF, % 203.1 (74.1)* 161.8 (61.2)
ESR, mm/h 18.6 (16.7) —
CRP, mg/L 13.6 (13.9) —
DAS28 3.62 (1.4) —
HAQ 0.65 (0.6) —
Data is given as mean value (standard deviation).
(*) = 0.059, * P < 0.05, ** P < 0.01, *** P < 0.001.
CRP, C-reactive protein; DAS28, disease activity score; ESR, erythrocyte
sedimentation rate; MCP-1, monocyte chemotactic protein-1; HAQ, health
assessment questionnaire; PAI-1, plasminogen activator inhibitor-1; tPA, tissue
plasminogen activator; RA, rheumatoid arthritis; sICAM-1, soluble intercellular
adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1;
VWF, VonWillebrand factor.
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any of the variables studied (data not shown).
Several of the endothelial biomarkers were related to
traditional CV risk factors as well as to markers of
inflammation in the patient cohort (Table 5). Further-
more, there was a strong relation between MCP-1 and
tPA-mass (b = 13.813, P < 0.001) in patients with RA.
Sex and, in particular age, were strong predictors for
some of the endothelial biomarkers. In a multiple linear
regression model taking into account solely the predic-
tive value of the endothelial biomarkers for increased
IMT in patients with RA, VWF and MCP-1 were the
best predictors (Table 6, model 1). When the data were
adjusted for disease activity, the same relations were still
apparent (Table 6, model 2).
In the same model, but with ED-FMD in RA as the
response variable, sL-selectin was a highly significant
predictor (Table 7, model 1). This was true also in a
model where only the variables that were significant in
simple regression (i.e. PAI-1 and sL-selectin) were tested
(data not shown). Again, when the data was adjusted for
disease activity, this relation was maintained (Table 7,
model 2). These predictive values for the biomarkers
remained after further adjustment for systolic blood
pressure and smoking (data not shown).
When the same models were tested for the controls,
tPA-mass was the best predictor for IMT (b =0 . 1 8 ,P <
0.01) and MCP-1 for ED-FMD (b = -37.85, P < 0.05).
Ultrasound measurements at 18 months
In the subgroup that was re-evaluated 18 months after
the first ultrasound measurement, the IMT had
increased significantly among the RA patients to (mean
(standard deviation) at 18 months) 0.57 ((0.15); P <
0.05). Among the controls the IMT after 18 months was
0.54 ((0.13); not significant). The endothelium-depen-
dent vasodilatation did not change significantly neither
among the RA patients nor among the controls (106.9
(5.2) and 107.5 (4.4), respectively; not significant).
There were no statistically significant differences in
the difference in changes of the measurements, that is,
delta values, between RA patients and controls after
18 months (data not shown).
Discussion
We found no impairment of the endothelial function,
measured as ED-FMD, among patients with newly diag-
nosed RA compared with controls. There have been, to
the best of our knowledge, only two previous studies on
ED-FMD in newly diagnosed RA patients [19,35]. In
Table 4 Simple linear regression models of associations
between some of the traditional risk factors for CVD,
markers of inflammation and endothelial biomarkers and
IMT or ED-FMD in 79 patients with early RA
IMT ED-FMD
b P b P
Sex, female -1.02/+ 0.005 3.82/+ 0.002
Age 0.001/year <0.001 - 0.178/year <0.001
Systolic BP 0.030/mmHg 0.001
† ns
Cholesterol 0.004/mmol L
-1 0.027
† ns
Smoking, years 0.029/year 0.005
† ns
Snuff, years 0.043/year 0.027
† ns
PAI-1 ns -0.026/μgL
-1 0.064
†
tPA-mass 73.0/μgL
-1 0.005
† ns
VWF 5.914/% 0.003
† ns
sL-selectin -1.058/ng mL
-1 0.026
† 4.961/ng mL
-1 0.004
†
MCP-1 4.650/pg mL
-1 0.002 ns
† Not significant after adjustment for sex and/or age.
BP, blood pressure; CVD, cardiovascular disease; ED-FMD, endothelial
dependent flow mediated dilatation; IMT, intima media thickness; MCP-1,
monocyte chemotactic protein-1; ns, Not significant; PAI-1, plasminogen
activator inhibitor-1; RA, rheumatoid arthritis; tPA, tissue plasminogen
activator; VWF, VonWillebrand factor.
Table 5 Simple linear regression models of associations between endothelial biomarkers and sex, age, blood pressure
or DAS28 in 79 patients with early RA
Sex (female) Age Systolic BP DAS28
b P b P b P b P
PAI-1 -22.1/+ 0.034 0.84/year 0.033 0.58/mmHg 0.045
† 6.40/unit 0.048
†
tPA-mass -2.2/+ 0.008 0.11/year 0.001 0.064/mmHg 0.008
† 0.50/unit 0.045
†
VWF ns 3.36/year <0.001 1.53/mmHg 0.012
† ns
sVCAM-1 ns ns ns -48.1/unit 0.020
sICAM-1 ns 2.76/year 0.048 ns ns
sE-selectin ns ns ns 2.99/unit 0.073
sL-selectin 267.2/+ 0.002 -14.4/year <0.001 -6.9/mmHg 0.008
† -63.8/unit 0.001
MCP-1 ns 21.3/year 0.031 15.5/mmHg 0.046
† ns
†Not significant after adjustment for sex and/or age.
BP, blood pressure; DAS28, disease activity score; MCP-1, monocyte chemotactic protein-1; ns, not significant; PAI-1, plasminogen activator inhibitor-1; RA,
rheumatoid arthritis; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; tPA, tissue plasminogen activator;
VWF, VonWillebrand factor.
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lium-dependent vasodilatation. However, our study
comprises four to eight times more patients with RA
than those studies, which might in part explain the dif-
ferent results.
There was no significant difference in IMT in patients
with early RA compared with controls. There are few
studies evaluating atherosclerosis in newly diagnosed RA
patients. In two recent studies, RA patients had an
increased IMT compared with healthy controls [36,37].
Those studies comprised older patients with higher
inflammatory activity than those in the present study.
Moreover, there were several other methodological dif-
ferences compared with thep r e s e n ts t u d yt h a tm i g h t
explain the different results. Also, in another recent
study, evaluating coronary calcification in early RA,
there were no difference in atherosclerosis compared
with controls [38]. However, in a tentative follow-up
after 18 months we found a significant increase in the
IMT among patients with RA while there was no
equivalent significant change in the control group. This
increase was significant although all patients with RA
were treated with DMARDs and had a low inflammatory
activity. In longstanding RA we have previously demon-
strated an increased IMT [7], a finding later confirmed
by other investigators [6,8]. Also in patients with long-
standing RA an increase in IMT has been shown even
though efficient treatment with anti-TNF therapy [39].
One recent epidemiological study showed an increased
incidence of CVD, as measured by myocardial infarc-
tion, in patients with RA during the two years prior to
diagnosis [40]. The authors concluded that their results
could imply the presence of inflammatory-triggered
atherosclerosis before overt symptoms and diagnosis of
RA.
We also wanted to identify endothelial biomarkers
reflecting the early atherosclerotic process in RA. Thus,
we evaluated the involvement of adhesion molecules,
MCP-1 and endothelially produced haemostatic factors
in endothelial dysfunction and very early atherosclerosis,
as measured by ED-FMD and IMT, respectively. Simple
regression analyses revealed that decreased sL-selectin
was strongly related to a lower ED-FMD in RA and
associated with an increased IMT in both RA and con-
trols. A lower level of sL-selectin has been associated
with CVD in the general population [24]. L-selectin is
expressed on leucocytes and is also known to be
involved in the initial leukocyte rolling on activated
endothelium [24]. L-selectin has been shown to be
downregulated during chronic inflammation. We found
a strong inverse relation between sL-selectin and
DAS28, which reflects the current inflammatory status
in RA. In multiple linear regression models, evaluating
the impact of endothelial biomarkers on endothelial
function and adjusting for inflammation, sL-selectin was
still strongly related to ED-FMD and also close to signif-
icantly related to IMT. This implies a durable relation
between sL-selectin and endothelial function in early
RA, a relation that does not seem to be mediated simply
via inflammatory disease activity. This is a new finding
that warrants further investigation of pathophysiological
mechanisms beyond the inflammatory pathway.
Regarding the other adhesion molecules, sVCAM-1
and sICAM-1 showed higher levels in RA than in con-
trols; however, we did not find any independent rela-
tions with any of the ultrasound measurements among
our relatively young patients with early RA. Although, in
agreement with the findings of others, some of the
adhesion molecules showed relations to measures of
inflammation [27]. In previous studies on older patients
with long-standing RA, several of these markers corre-
lated with IMT [26,27]. The inflammatory status of the
present patient cohort was, however, low and of short
duration, leading to less stress on the endothelium.
MCP-1 was found to be a strong and independent
predictor of an increased IMT. This chemoattractant for
monocytes is secreted by activated endothelial cells and
Table 7 Multiple linear regression models of
inflammatory markers, and endothelial biomarkers with
ED-FMD as response variable in 79 patients with early RA
Model 1 Model 2
b 95% CI P b 95% CI P
VWF 6.594 -8.410; 21.598 0.384 5.099 -9.924; 20.122 0.501
tPA-mass -0.339 -0.716; 0.038 0.077 -0.366 -0.766; 0.034 0.072
sICAM-1 -2.682 -11.164; 5.799 0.530 -3.201 -11.840; 5.439 0.462
sL-selectin 5.125 1.708; 8.542 0.004 6.406 2.780; 10.033 0.001
MCP-1 4.476 -7.908; 16.860 0.474 6.387 -6.087; 18.862 0.311
ESR 0.048 -0.018; 0.114 0.114
CI, confidence interval; ED-FMD, endothelial dependent flow mediated
dilatation; ESR, erythrocyte sedimentation rate; MCP-1, monocyte chemotactic
protein-1; RA, rheumatoid arthritis; sICAM-1, soluble intercellular adhesion
molecule-1; tPA, tissue plasminogen activator; VWF, VonWillebrand factor.
Table 6 Multiple linear regression models of some of the
inflammatory markers, and endothelial biomarkers with
IMT as response variable in 79 patients with early RA
Model 1 Model 2
b 95% CI P b 95% CI P
VWF 4.420 0.617; 8.223 0.023 3.946 0.334; 7.557 0.033
tPA-mass 0.069 -0.027; 0.164 0.156 0.026 -0.070; 0.122 0.588
sICAM-1 0.200 -1.950; 2.349 0.854 0.616 -1.461; 2.693 0.556
sL-selectin -0.719 -1.585; 0.147 0.102 -0.759 -1.631; 0.112 0.087
MCP-1 3.117 -0.022; 6.256 0.052 3.406 0.407; 6.405 0.027
ESR -0.007 -0.023; 0.009 0.384
ESR, erythrocyte sedimentation rate; CI, confidence interval; IMT, intima media
thickness; MCP-1, monocyte chemotactic protein-1; RA, rheumatoid arthritis;
sICAM-1, soluble intercellular adhesion molecule-1; tPA, tissue plasminogen
activator; VWF, VonWillebrand factor.
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mation, the first step in atherosclerosis [23]. Moreover,
MCP-1 has been shown to promote plaque growth, to
be increased in acute CVD in the general population
[23] and to be correlated with IMT in uraemic patients
[22]. In the present study MCP-1 was related to tPA-
mass, which in turn was associated with markers of
inflammation both here and in other studies [41]. How-
ever, when adjusting for inflammation and other
endothelial biomarkers, the impact of MCP-1 on IMT
w a se v e nm o r es i g n i f i c a n t .W eh a v ep r e v i o u s l yf o u n d
increased MCP-1 to precede the diagnosis of RA in
anti-CCP or RF-positive individuals [42]. Previously, a
more atherogenic lipid profile, suggested to modify the
inflammatory reaction, has been shown to antedate the
diagnosis of RA by at least 10 years [43]. Taken
together, these findings are suggestive of a very early
endothelial activation in RA, possibly already present
before diagnosis.
Regarding the haemostatic factors, increased tPA-mass
was related to a higher IMT. There was also a tendency
towards a significant relation between increased PAI-1-
mass and impaired ED-FMD. Increased values for PAI-1
and tPA mass have been shown to be associated with an
increased risk of CVD in the general population [21,25]
as well as in patients with RA [26]. tPA is produced
endothelially and an increase in this biomarker might be
another reflection of an endothelial activation [21,25]. In
this study, there was a relation between tPA-mass and
DAS28 in patients with RA. Increasing PAI-1-mass was
also related to markers of inflammation. PAI-1 is an
acute-phase reactant and this finding is consistent with
our previous study in which PAI-1 was increased in RA
patients compared with controls [7]. Both tPA and PAI-
1 have also been shown to be associated with inflamma-
tion in patients with diabetes mellitus [41]. An increase
in these biomarkers leads to a prothrombotic state [21].
Furthermore, our finding that the level of VWF, another
endothelially produced haemostatic factor, was indepen-
dently related to the IMT, is in accordance with other
reports [8,21]. This relation also remained when
adjusted for ESR. Taken together, our findings implicate
a procoagulant state among our RA patients with newly
diagnosed RA.
It appears, as a result of this study, that sL-selectin,
being involved in the initial leukocyte rolling process, is
a strong predictor of the early endothelial activation in
RA, as measured by ED-FMD, whereas MCP-1 and
VWF are indicators of increasing IMT, a later phase of
the early atherosclerotic process. Corresponding results
were not found in the control group.
In the RA group, the IMT was higher among men
than females, and IMT also increased with age, higher
systolic blood pressure, higher cholesterol and a longer
period of smoking or using oral snuff. Also, there was a
decrease in ED-FMD in men compared with women,
ED-FMD decreased with increasing age and increasing
systolic blood pressure. All of these findings are in line
with studies on the general population [11,12,14] or
patients with established RA [4].
Our ongoing study is one of the first to investigate
the ED-FMD and IMT prospectively among newly
diagnosed patients with RA. A strength of the study is
that in northern Sweden nearly all patients with newly
diagnosed RA are included in a structured follow up.
All patients aged 60 years or younger were asked to
participate in this study within 12 months of their
diagnosis. As our main interest is to evaluate the
impact of inflammation and endothelial activation on
the early atherosclerotic process prospectively over a
long time, a young cohort comprising patients with
very early RA will be less affected by obscuring gener-
alised atherosclerosis [42] and by other comorbidities
and mortality in the coming decades. Moreover, as
inflammation seems to be relatively more important
for the atherosclerotic progression in younger patients
[4] this cohort should, however, be ideal for unmask-
ing any difference prospectively. Although it may have
rendered it more difficult to determine baseline differ-
ences in RA vs. controls, the design allows repeated
analyses in a comparably large cohort. The first
follow-up only 18 months after the initial ultrasound
measurement could be accomplished in only a sub-
group. Nevertheless, this provided a unique opportu-
nity to investigate rapid changes in the measurements
of atherosclerosis among patients with RA. A com-
plete follow-up in all RA patients and controls five
years after the first ultrasound investigation is in
progress. Another strength of this study was that the
same person (EL) undertook all of the ultrasound
measurements, thereby eliminating interpersonal var-
iation. A limitation is that there was only one control
per two RA patients, which could decrease the statisti-
cal power in the control group. Both the control
group and, in particular, the RA-group are, however,
larger than in most previous studies on RA using this
technique. Furthermore, our main focus regarding
associations between physiological measures and bio-
markers was in the larger RA-group. Another limita-
tion could be that all individuals were already on and
continued their medications, including DMARDs, cor-
ticosteroids, non-steroidal anti-inflammatory drugs
and coxibs throughout the ultrasound measurement,
due to the fact that this work is part of a prospective
observational study. Medications at the first ultra-
sound investigation, or up until the first follow-up,
had however no statistically significant influence on
the results.
Södergren et al. Arthritis Research & Therapy 2010, 12:R158
http://arthritis-research.com/content/12/4/R158
Page 7 of 9Taken together, our results point towards an ongoing
endothelial activation among patients with early RA.
This endothelial activation was not translated into
endothelial dysfunction, as measured by ED-FMD.
Changes of ED-FMD can be rapid and could have
reflected a high inflammatory activity if present. The
variability of IMT is complex and therefore more inert
to temporary changes. A more sensitive physiological
method would possibly have been able to uncover a
relation. However, there were differences in the levels of
biomarkers, indicating endothelial activation in early RA
to be related to the disease process, yet independent of
acute-phase reaction. Also, after 18 months this had
been translated into a significant increase of athero-
sclerosis as measured by IMT, not evident among the
controls. Furthermore, more biomarkers were related to
the physiological measurements within the RA patient
cohort than among the controls, while the controls
exhibited more relations between the physiological mea-
surements and traditional CVD risk factors. This sup-
ports the hypothesis that the disease process in RA is
involved in early endothelial activation and atherosclero-
sis, in a way distinguished from the general population.
This possibly indicates that the endothelial activating
process also has a different course compared with that
leading to joint destruction in RA. In previous studies of
patients with long-standing RA, in whom endothelial
activation had continued for several years, the IMT was
consistently shown to be increased compared with con-
trols [6-9].
Conclusions
In conclusion, we found no signs of increased athero-
sclerosis, as assessed by IMT and ED-FMD measure-
ments, among patients with newly diagnosed RA
compared with healthy controls. However, both IMT
and ED-FMD were related to several biomarkers of
endothelial activation, mainly to MCP-1 and sL-selectin,
respectively. This may implicate an endothelial activa-
tion occurring very early in the course of RA preceding
signs of endothelial dysfunction and premature athero-
sclerosis, as measured by ED-FMD and IMT. Consider-
ing the current state of knowledge, the necessity of
optimising prevention and treatment of CVD in patients
with RA must be emphasised.
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